Drug intelligence / Profile preview

minretumomab

Development stage: Discontinued
Lead developer: EUSA Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Minretumomab is a murine monoclonal antibody that targets the tumor-associated glycoprotein 72 (TAG-72), which is expressed on the surface of various adenocarcinomas. It was primarily developed as a radiolabeled antibody for use in radioimmunotherapy and diagnostic imaging of cancers such as colorectal, ovarian, and other epithelial-derived tumors. Minretumomab binds specifically to TAG-72 on cancer cells, allowing for targeted delivery of radioactive isotopes or imaging agents to tumor sites. The drug was originally developed by Cytogen.

Other names: minretumomabCC49CC-49CC 49

Targets

TAG-72

Beyond the preview

Go deeper on minretumomab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on minretumomab.

Explore the full profile